Sudeep Pharma FY26 Net Profit ₹174.3 Cr, Declares ₹1.50 Dividend

• Board approved audited standalone and consolidated financial results for Q4 and FY ended 31 March 2026, with consolidated net profit of ₹174.28 crore.
• Recommended a final dividend of ₹1.50 (150%) per equity share of ₹1 each for FY26, subject to shareholder approval at AGM.
• Appointed M/s. Chetan Gandhi & Associates as Cost Auditor and M/s H M Mehta & Associates as Secretarial Auditor for FY27 and 5 years respectively.
• Company completed its IPO on 28 November 2025, raising ₹9,500 lakhs in fresh issue and listing on NSE and BSE.